BAL fluid protein profiles at study onset and completion
| . | No. . | TNF-α and soluble receptors . | Proinflammatory cytokines . | T-cell cytokines . | |||||
|---|---|---|---|---|---|---|---|---|---|
| TNF-α, pg/mL . | TNFRI, pg/mL . | TNFRII, pg/mL . | IL-6, pg/mL . | IL-1β, pg/mL . | IL-2, pg/mL . | INF-γ, pg/mL . | |||
| Control | 5 | 5.4 ± 1.6 | 21 ± 3 | 16 ± 0.8 | 1.6 ± 0.7 | 1.3 ± 0.5 | 2.6 ± 1.1 | 7.5 ± 1.8 | |
| IPS-Dx (All) | 11 | 126 ± 59* | 892 ± 158* | 1071 ± 278* | 4715 ± 2167* | 7.1 ± 3.6 | 10.7 ± 4.8 | 4.4 ± 1.6 | |
| IPS-Dx (NR) | 3 | 215 ± 69 | 1345 ± 215 | 2007 ± 670 | 5115 ± 3388 | 6.3 ± 3.8 | 16.7 ± 9.5 | 11.3 ± 2.3 | |
| IPS-Dx (Resp) | 5 | 144 ± 120 | 846 ± 232 | 6219 ± 3800 | 10.6 ± 7.7 | 4.1 ± 2.3 | 1.2 ± 1.2 | ||
| IPS-post (Resp) | 5 | 12 ± 2† | 157 ± 53§ | 362 ± 144† | 4.4 ± 0.7‡ | 1.5 ± 0.6 | 0.8 ± 0.8 | 1.5 ± 1.0 | |
| . | . | LPS activation cascade . | Anti-inflammatory cytokines . | Proinflammatory chemokines . | Capillary leak . | ||||
| sCD14, ng/mL . | LBP, ng/mL . | IL-1ra, pg/mL . | TGF-β, pg/mL . | IL-8, pg/mL . | MCP-1, pg/mL . | Protein, μg/mL . | |||
| Control | 5 | LOD | UD | 94 ± 17 | UD | 32 ± 5.8 | 43 ± 10 | 59 ± 5 | |
| IPS-Dx (All) | 11 | 59 ± 30* | 0.6 ± 0.4* | 2513 ± 1306* | UD | 2373 ± 1295* | 20 784 ± 8304* | 1845 ± 357* | |
| IPS-Dx (NR) | 3 | 106 ± 106 | 0.2 ± 0.8 | 1220 ± 610 | UD | 2030 ± 1117 | 33 235 ± 20 333 | 2219 ± 176 | |
| IPS-Dx (Resp) | 5 | 64 ± 25 | 1.1 ± 0.8 | 3746 ± 2600 | UD | 4069 ± 2450 | 32 647 ± 15 266 | 2358 ± 505 | |
| IPS-post (Resp) | 5 | 2.9 ± 1.2‡ | UD‡ | 821 ± 262 | UD | 545 ± 375† | 1060 ± 777† | 505 ± 46‡ | |
| . | No. . | TNF-α and soluble receptors . | Proinflammatory cytokines . | T-cell cytokines . | |||||
|---|---|---|---|---|---|---|---|---|---|
| TNF-α, pg/mL . | TNFRI, pg/mL . | TNFRII, pg/mL . | IL-6, pg/mL . | IL-1β, pg/mL . | IL-2, pg/mL . | INF-γ, pg/mL . | |||
| Control | 5 | 5.4 ± 1.6 | 21 ± 3 | 16 ± 0.8 | 1.6 ± 0.7 | 1.3 ± 0.5 | 2.6 ± 1.1 | 7.5 ± 1.8 | |
| IPS-Dx (All) | 11 | 126 ± 59* | 892 ± 158* | 1071 ± 278* | 4715 ± 2167* | 7.1 ± 3.6 | 10.7 ± 4.8 | 4.4 ± 1.6 | |
| IPS-Dx (NR) | 3 | 215 ± 69 | 1345 ± 215 | 2007 ± 670 | 5115 ± 3388 | 6.3 ± 3.8 | 16.7 ± 9.5 | 11.3 ± 2.3 | |
| IPS-Dx (Resp) | 5 | 144 ± 120 | 846 ± 232 | 6219 ± 3800 | 10.6 ± 7.7 | 4.1 ± 2.3 | 1.2 ± 1.2 | ||
| IPS-post (Resp) | 5 | 12 ± 2† | 157 ± 53§ | 362 ± 144† | 4.4 ± 0.7‡ | 1.5 ± 0.6 | 0.8 ± 0.8 | 1.5 ± 1.0 | |
| . | . | LPS activation cascade . | Anti-inflammatory cytokines . | Proinflammatory chemokines . | Capillary leak . | ||||
| sCD14, ng/mL . | LBP, ng/mL . | IL-1ra, pg/mL . | TGF-β, pg/mL . | IL-8, pg/mL . | MCP-1, pg/mL . | Protein, μg/mL . | |||
| Control | 5 | LOD | UD | 94 ± 17 | UD | 32 ± 5.8 | 43 ± 10 | 59 ± 5 | |
| IPS-Dx (All) | 11 | 59 ± 30* | 0.6 ± 0.4* | 2513 ± 1306* | UD | 2373 ± 1295* | 20 784 ± 8304* | 1845 ± 357* | |
| IPS-Dx (NR) | 3 | 106 ± 106 | 0.2 ± 0.8 | 1220 ± 610 | UD | 2030 ± 1117 | 33 235 ± 20 333 | 2219 ± 176 | |
| IPS-Dx (Resp) | 5 | 64 ± 25 | 1.1 ± 0.8 | 3746 ± 2600 | UD | 4069 ± 2450 | 32 647 ± 15 266 | 2358 ± 505 | |
| IPS-post (Resp) | 5 | 2.9 ± 1.2‡ | UD‡ | 821 ± 262 | UD | 545 ± 375† | 1060 ± 777† | 505 ± 46‡ | |
Protein levels were measured in the BAL fluid collected from all subjects with IPS at the time of diagnosis (IPS-Dx [All]) and compared BAL fluid levels in normal individuals (Control). For the 5 subjects who achieved CR and underwent a second BAL procedure, data are provided at the time of initial IPS diagnosis (IPS-Dx [Resp]) and at the end of study therapy (IPS-post [Resp]). Data are as mean plus or minus SEM. No differences were observed in BAL protein levels between responders and nonresponders at the time of diagnosis, IPS-Dx (Resp) versus IPS-Dx (NR).
Resp indicates responders; UD, undetectable; and LOD, limits of detection.
P < .01: IPS-Dx (All) vs Control.
P < .05 IPS-post (Resp) vs IPS-Dx (Resp).
P < .01 IPS-post (Resp) vs IPS-Dx (Resp).